Back

Advanced Prostate Cancer After ESMO 2026 Discussion of Treatment Intensification From High-Risk Localized to Metastatic Disease, Agent Selection, and Emerging Epigenetic Targets

Advanced Prostate Cancer After ESMO 2026 Discussion of Treatment Intensification From High-Risk Localized to Metastatic Disease, Agent Selection, and Emerging Epigenetic Targets

Four prostate cancer experts discuss ESMO 2026 data on treatment intensification from high-risk localized to metastatic hormone-sensitive disease, choosing among treatments, cognitive effects, options in castration-resistant disease, and EZH2inhibition with mevrometostat.

Advanced Prostate Cancer After ESMO 2026 Discussion of Treatment Intensification From High-Risk Localized to Metastatic Disease, Agent Selection, and Emerging Epigenetic Targets

Episodes

All
All